Arcus biosciences, inc. (RCUS)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
ASSETS
Current assets:
Cash and cash equivalents

67,326

57,937

78,992

76,068

68,499

71,064

74,889

169,998

198,116

98,426

Short-term investments

90,540

130,333

111,997

148,330

173,436

185,480

182,948

95,700

82,064

77,277

Receivable from collaboration partners

344

132

5,276

-

-

-

5,000

-

-

-

Prepaid expenses and other current assets

8,007

4,303

4,223

3,273

3,080

2,321

2,329

1,550

1,834

1,141

Amounts owed by a related party

-

-

0

62

0

83

114

193

54

25

Total current assets

166,217

192,705

200,488

227,733

245,015

258,948

265,280

267,441

282,068

176,869

Long-term investments

-

-

5,992

0

1,201

3,181

7,746

11,792

10,595

-

Property and equipment, net

8,761

9,330

10,011

10,362

11,026

11,107

11,762

12,513

11,813

11,230

Equity investment in related party

-

-

0

357

770

1,202

1,525

1,711

515

682

Restricted cash

203

203

203

203

203

203

203

203

203

203

Other long-term assets

963

872

263

319

315

284

205

205

205

1,502

Total assets

176,144

203,110

216,957

238,974

258,530

274,925

286,721

293,865

305,399

190,486

LIABILITIES
Current liabilities
Accounts payable

2,426

4,704

2,905

2,448

2,829

3,102

2,109

5,388

3,920

3,820

Accrued liabilities

10,170

9,522

9,662

15,552

7,629

6,023

6,667

4,342

3,610

3,137

Deferred revenue, current

7,000

7,000

-

-

-

-

-

-

-

-

Deferred revenue, current

-

-

7,000

7,000

7,000

6,250

6,250

5,000

5,000

5,000

Other current liabilities

1,408

1,480

1,490

1,513

1,545

1,560

1,585

1,650

1,732

769

Total current liabilities

21,004

22,706

21,057

26,513

19,003

16,935

16,611

16,380

14,262

12,726

Deferred revenue, noncurrent

10,272

12,022

-

-

-

-

-

-

-

-

Deferred revenue, noncurrent

-

-

13,772

10,522

12,272

16,984

18,546

16,087

17,337

18,587

Deferred rent

3,590

3,734

3,875

4,010

4,145

4,272

4,396

4,516

4,655

4,740

Other long-term liabilities

640

806

1,026

1,283

1,543

1,792

2,047

2,308

2,554

565

Total liabilities

35,506

39,268

39,730

42,328

36,963

39,983

41,600

39,291

38,808

36,618

Convertible preferred stock, $0.0001 par value, no shares and 120,958,867 shares authorized as of December 31, 2018 and 2017, respectively; no shares and 30,459,574 shares issued and outstanding as of December 31, 2018 and 2017, respectively

-

-

-

-

-

-

0

0

0

226,196

Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares issued and outstanding as of March 31, 2020 and December 31, 2019

0

0

0

0

0

0

0

0

0

-

Common stock, $0.0001 par value, 400,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 45,982,788 and 45,925,004 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

4

4

4

4

4

4

4

4

4

-

Additional paid-in capital

373,425

369,100

365,898

362,905

359,820

357,873

355,758

354,375

352,872

948

Accumulated deficit

-233,079

-205,326

-188,728

-166,376

-138,286

-122,828

-110,533

-99,722

-86,188

-73,234

Accumulated other comprehensive income

288

64

53

113

29

-107

-108

-83

-97

-42

Total stockholders’ equity

140,638

163,842

177,227

196,646

221,567

234,942

245,121

254,574

266,591

-72,328

Total liabilities, convertible preferred stock and stockholders’ equity

176,144

203,110

216,957

238,974

258,530

274,925

286,721

293,865

305,399

190,486